C-CAR168 for Multiple Sclerosis
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a global, multicenter, Phase 1b/2 study evaluating the safety and efficacy of C-CAR168, an autologous anti-CD20/BCMA chimeric antigen receptor T-cell therapy, in participants with progressive multiple sclerosis refractory to standard-of-care therapy. The study includes participants with secondary progressive multiple sclerosis (SPMS) and primary progressive multiple sclerosis (PPMS).
Who Is on the Research Team?
Yihong Yao, PhD
Principal Investigator
AbelZeta Inc.
Are You a Good Fit for This Trial?
This trial is for adults aged 18-55 with progressive multiple sclerosis (either active or non-active SPMS, or PPMS) who have not improved after at least one strong MS treatment. Participants must be able to walk (with some disability), meet health and safety requirements, and show worsening symptoms in the past two years.Inclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- C-CAR168
Trial Overview
The study tests C-CAR168, a personalized cell therapy made from the patient's own immune cells that are modified to target specific proteins linked to MS. The main goals are to check its safety and how well it works in people whose MS hasn't responded to standard treatments.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Participants will receive: Leukapheresis Fludarabine Cyclophosphamide Single intravenous infusion of C-CAR168
Find a Clinic Near You
Who Is Running the Clinical Trial?
AbelZeta Inc.
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.